➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Colorcon
AstraZeneca
McKesson
Express Scripts

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Crenolanib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Crenolanib?

Crenolanib is an investigational drug.

There have been 17 clinical trials for Crenolanib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Arog Pharmaceuticals, Inc., St. Jude Children's Research Hospital, and University of Ulm.

There are ten US patents protecting this investigational drug and one hundred and forty-three international patents.

Recent Clinical Trials for Crenolanib
TitleSponsorPhase
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaArog Pharmaceuticals, Inc.Phase 2
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLArog Pharmaceuticals, Inc.Phase 3
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLArog Pharmaceuticals, Inc.Phase 3

See all Crenolanib clinical trials

Clinical Trial Summary for Crenolanib

Top disease conditions for Crenolanib
Top clinical trial sponsors for Crenolanib

See all Crenolanib clinical trials

US Patents for Crenolanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Crenolanib   Start Trial Method of inhibiting mutant C-KIT Arog Pharmaceuticals, Inc. (Dallas, TX)   Start Trial
Crenolanib   Start Trial Benzoimidazole derivatives useful as antiproliferative agents Pfizer Inc (New York, NY)   Start Trial
Crenolanib   Start Trial Processes for the preparation of benzoimidazole derivatives Pfizer Inc (New York, NY)   Start Trial
Crenolanib   Start Trial Method of inhibiting constitutively active phosphorylated FLT3 kinase AROG Pharmaceuticals, LLC (Dallas, TX)   Start Trial
Crenolanib   Start Trial Crenolanib for treating FLT3 mutated proliferative disorders AROG PHARMACEUTICALS, INC. (Dallas, TX)   Start Trial
Crenolanib   Start Trial Crenolanib for treating FLT3 mutated proliferative disorders AROG PHARMACEUTICALS, INC. (Dallas, TX)   Start Trial
Crenolanib   Start Trial Method of inhibiting mutant C-kit AROG PHARMACEUTICALS, INC. (Dallas, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Crenolanib

Drugname Country Document Number Estimated Expiration Related US Patent
Crenolanib Australia AU2013204841 2032-09-26   Start Trial
Crenolanib Canada CA2812258 2032-09-26   Start Trial
Crenolanib China CN103655563 2032-09-26   Start Trial
Crenolanib China CN109010340 2032-09-26   Start Trial
Crenolanib Japan JP2014065696 2032-09-26   Start Trial
Crenolanib Japan JP6042157 2032-09-26   Start Trial
Crenolanib South Korea KR101886006 2032-09-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Colorcon
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.